|
KMID : 0624620200530060291
|
|
BMB Reports
2020 Volume.53 No. 6 p.291 ~ p.298
|
|
|
Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer
|
|
Lim Dan-Saem
Do Yeo-Jin
Kwon Byung-Su
Chang Woo-Chul
Lee Myeong-Sok
Kim Jong-Min
Cho Jin-Gu
|
|
|
Abstract
|
|
|
|
Tumor angiogenesis is an essential process for growth and metastasis of cancer cells as it supplies tumors with oxygen and nutrients. During tumor angiogenesis, many pro-angiogenic factors are secreted by tumor cells to induce their own vascularization via activation of pre-existing host endothelium. However, accumulating evidence suggests that vasculogenic mimicry (VM) is a key alternative mechanism for tumor vascularization when tumors are faced with insufficient supply of oxygen and nutrients. VM is a tumor vascularization mechanism in which tumors create a blood supply system, in contrast to tumor angiogenesis mechanisms that depend on pre-existing host endothelium. VM is closely associated with tumor progression and poor prognosis in many cancers. Therefore, inhibition of VM may be a promising therapeutic strategy and may overcome the limitations of anti-angiogenesis therapy for cancer patients. In this review, we provide an overview of the current anti-angiogenic therapies for ovarian cancer and the current state of knowledge regarding the links between microRNAs and the VM process, with a focus on the mechanism that regulates associated signaling pathways in ovarian cancer. Moreover, we discuss the potential for VM as a therapeutic strategy against ovarian cancer.
|
|
|
KEYWORD
|
|
|
Angiogenesis, Ovarian cancer, Therapeutic target, Tumor vascularization, Vasculogenic mimicry
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|